| |
|
|
|
GTC Company, Global Technology Community 434 W. Foothill Blvd Monrovia, CA 91016
2012-05-30
Despite the hundreds of kinase inhibitors currently in discovery and pre-clinical phases, the number of kinase inhibitors which have been approved and are on the market remains low by comparison. This discrepancy reflects the challenges which accompany the development of ATP-competitive kinase inhibitors, including low specificity and off-target binding. There is also the problem of gatekeeper-associated drug resistance. To remain competitive in the kinase field, it will require you to stay abreast with recent development trends and technological advancements aimed at circumventing these issues. We will also provide you with a broad overview of the role kinases play in various types of cancer as well as introduce you to several novel kinases and inhibitor candidates.
|
|
|
|
|
|
|
|
Organized by:
|
|
GTC |
|
|
Invited Speakers:
|
|
Alex Bullock, Ph.D.
Principal Investigator
SGC, University of Oxford | | | Thomas Chan
ArQule | | | Xianming Deng, Ph.D.
Principal Investigator
School of life sciences, Xiamen University | | | Thomas A. Engler, Ph.D.
Senior Research Advisor, Discovery Chemistry Research and Technologies
Eli Lilly | | | Nathanael Gray, Ph.D.
Associate Professor, Department of Biological Chemistry and Molecular Pharmacology
Harvard Medical School
Cancer Biology
Dana-Farber Cancer Institute | | | Richard Lewis, Ph.D.
Principal Scientist
Amgen | | | Min Liu, Ph.D.
Instructor in Neurology, Neurology
Brigham and Women's Hospital | | | Matthew Lucas
Senior Scientist
Hoffmann La Roche | | | Jeffrey R Peterson, Ph.D.
Associate Professor
Fox Chase Cancer Center | | | Leo Price, Ph.D.
Leiden Amsterdam Center for Drug Research | | | Gary L. Schieven, Ph.D.
Research Fellow, Immunology Drug Discovery
Bristol-Myers Squibb | | | Markus Seeliger
Assistant Professor, Pharmacological Sciences
Stony Brook University Medical School | | | Juswinder Singh, Ph.D.
Co-Founder & Chief Scientific Officer
Avila Therapeutics | | | Matthew Soellner, Ph.D.
Assistant Professor, Medicinal Chemistry
University of Michigan | | | Michael B Yaffe , M.D., Ph.D.
David H. Koch Professor, Koch Institute for Integrative Cancer Research,
Depts of Biology and Biological Engineering and Division of Health Sciences and Technology;
Senior Associate Member, Broad Institute
Massachusetts Institute of Technology |
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2012-05-31
|
|
|
|
|
|
|
|
Registration:
|
|
GTCbio is proud to present our 7th Protein Kinases in Drug Discovery Conference! This meeting will be held May 30-31, 2012 at the Hyatt Harbor Hotel in historical Boston, Massachusetts, one of the most concentrated academic and industrial areas in the United States. We will bring together industry leaders from major pharmaceutical companies, biotech companies as well as top researchers from academia and government to provide you with a better understanding of the complex activities of kinases and some solutions to the challenges associated with kinase drug development. The meeting will offer you an intimate forum to engage in discourse with other distinguished researchers involved in the most cutting-edge kinase work!
|
|
|
E-mail:
|
|
ken.lin@gtcbio.com
|
|
|
|
|
|
|
|
|